Insights

Autophagy Focus Nine Square Therapeutics targets the autophagy/lysosomal pathway with genetically validated targets to address severe neurodegenerative diseases. This indicates potential sales opportunities for assay services, in vitro and in vivo models, and compound screening platforms focused on autophagy modulation.

Preclinical Momentum Multiple programs are advancing through preclinical development with lead optimization aiming for IND-enabling studies. This readiness suggests demand for translational services, GMP chemistry support, and early Safety Pharmacology collaborations.

Strategic Partnerships Founded by ATP and UCSF scientists with notable investor and grant support from MJFF, signaling openness to co-development, funding-enabled partnerships, and opportunities for external collaboration on target validation, biomarkers, and companion diagnostics.

Funding Confidence Recent Series A of fifty million dollars and a four-and-a-half million grant combined indicate strong financial backing and potential for multi-year BD discussions, enabling larger deal opportunities for licensing, joint ventures, or milestone-based collaborations.

Clinical Readiness Path Focus on neurodegenerative disease targets with lead optimization on IND-enabling studies aligns with timing for CRO/CMC partnerships, regulatory strategy consulting, and scalable manufacturing services to support upcoming clinical programs.

Similar companies to Nine Square Therapeutics

Nine Square Therapeutics Tech Stack

Nine Square Therapeutics uses 8 technology products and services including gstatic.com, WordPress, Google Workspace, and more. Explore Nine Square Therapeutics's tech stack below.

Nine Square Therapeutics's Email Address Formats

Nine Square Therapeutics uses at least 4 email formats:
Nine Square Therapeutics Email FormatsExamplePercentage
FLast@ninesquaretx.comJDoe@ninesquaretx.com
86%
First.Last@ninesquaretx.comJohn.Doe@ninesquaretx.com
6%
Last@ninesquaretx.comDoe@ninesquaretx.com
5%
FirstL@ninesquaretx.comJohnD@ninesquaretx.com
3%

Frequently Asked Questions

What is Nine Square Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Nine Square Therapeutics's official website is ninesquaretx.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Nine Square Therapeutics generate?

Minus sign iconPlus sign icon
As of August 2026, Nine Square Therapeutics's annual revenue is estimated to be $1M - $10M.

What is Nine Square Therapeutics's SIC code and NAICS code?

Minus sign iconPlus sign icon
Nine Square Therapeutics's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Nine Square Therapeutics have currently?

Minus sign iconPlus sign icon
As of August 2026, Nine Square Therapeutics has approximately 10 employees across 3 continents, including North America, Asia and Europe. Key team members include Founder: S. L. and Senior Scientist: J. E. Explore Nine Square Therapeutics's employee directory with LeadIQ.

What industry does Nine Square Therapeutics belong to?

Minus sign iconPlus sign icon
Nine Square Therapeutics operates in the Biotechnology Research industry.

What technology does Nine Square Therapeutics use?

Minus sign iconPlus sign icon
Nine Square Therapeutics's tech stack includes gstatic.com, WordPress, Google Workspace, Microsoft 365, Priority Hints, WP Engine, PHP and GoDaddy.

What is Nine Square Therapeutics's email format?

Minus sign iconPlus sign icon
Nine Square Therapeutics's email format typically follows the pattern of FLast@ninesquaretx.com. Find more Nine Square Therapeutics email formats with LeadIQ.

How much funding has Nine Square Therapeutics raised to date?

Minus sign iconPlus sign icon
As of August 2026, Nine Square Therapeutics has raised $55M in funding. The last funding round occurred on Sep 12, 2023 for $4.5M.

When was Nine Square Therapeutics founded?

Minus sign iconPlus sign icon
Nine Square Therapeutics was founded in 2020.
Nine Square Therapeutics logo

Nine Square Therapeutics

Biotechnology ResearchCalifornia, United States2-10 Employees

Nine Square Therapeutics is a biotechnology research company that combines machine learning-driven image-based cell profiling with chemistry and computational science to accelerate the development of new drugs. Its focus is on creating first-in-class candidates targeting the autophagy/lysosomal pathway, with the aim of addressing severe neurodegenerative diseases that have historically posed treatment challenges. The company is developing a diversified portfolio of preclinical programs, with lead optimization progressing toward IND-enabling studies, reflecting a goal of advancing therapeutics efficiently from discovery to early clinical development. Based in South San Francisco, California, Nine Square was founded through collaboration between ATP, a life sciences venture capital firm, and UCSF scientists, situating it within a research-oriented biotech ecosystem.

Nine Square’s work targets genetically validated pathways implicated in neurodegeneration, positioning it within the biotechnology research industry as an early-stage drug discovery entity leveraging interdisciplinary methods to identify and optimize novel small molecules. Its activities are framed around advancing multiple programs through preclinical development, with recent leadership appointments indicating organizational growth and strategic direction. The company operates from a San Francisco area hub, aligning with a regional concentration of biotech innovation and venture activity.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2020
Employees
2-10

Section iconFunding & Financials

  • $55M

    Nine Square Therapeutics has raised a total of $55M of funding over 2 rounds. Their latest funding round was raised on Sep 12, 2023 in the amount of $4.5M as a Grant.

  • $1M - $10M

    Nine Square Therapeutics's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.